Table 1.
Demographic and clinical characteristics of main and external validation cohorts for ELISA analysis of sCDCP1
| Characteristic | Main cohort (n = 489) |
External validation cohort (n = 135) |
||
|---|---|---|---|---|
| Total (n = 489) | Training set (n = 326) | Test set (n = 163) | ||
| Male, n (%) | 211 (43.1) | 137 (42.0) | 74 (45.4) | 56 (41.5) |
| Age (years) | 31 (25, 36) | 31 (25, 37) | 31 (25, 35.5) | 31 (27, 36) |
| Disease stage, n (%) | ||||
| NL | 75 (15.3) | 56 (17.2) | 19 (11.7) | 30 (22.2) |
| NAFL | 223 (45.6) | 145 (44.5) | 78 (47.9) | 62 (45.9) |
| NASH | 191 (39.1) | 125 (38.3) | 66 (40.5) | 43 (31.9) |
| NAS score, n (%) | ||||
| 0–3 | 308 (63.0) | 210 (64.4) | 98 (60.1) | 99 (73.3) |
| 4–8 | 181 (37.0) | 116 (35.6) | 65 (39.9) | 36 (26.7) |
| Fibrosis, n (%) | ||||
| 0–1 | 377 (77.1) | 255 (78.2) | 122 (74.8) | 108 (82.2) |
| 2–4 | 112 (22.9) | 71 (21.8) | 41 (25.2) | 27 (17.8) |
| Diabetes, n (%) | 229 (46.8) | 139 (42.6) | 90 (55.2) | 44 (32.6) |
| BMI (kg/m2) | 38.2 (33.8, 43.6) | 38.4 (34.3, 43.8) | 37.9 (33.4, 42.3) | 37.9 (33.4, 42.6) |
| ALT (U/L) | 41.0 (25.0, 74.0) | 40.0 (25.0, 68.8) | 44.0 (25.0, 84.0) | 40.0 (25.5, 63.0) |
| AST (U/L) | 25.0 (18.0, 40.0) | 24.0 (18.0, 37.0) | 25.0 (18.0, 42.5) | 25.0 (18.0, 38.1) |
| γ-GT (U/L) | 34.0 (23.0, 61.0) | 32.5 (23.0, 57.8) | 38.0 (24.0, 69.0) | 33.0 (22.0, 53.0) |
| TG (mmol/L) | 1.61 (1.17, 2.21) | 1.61 (1.13, 2.16) | 1.65 (1.24, 2.36) | 1.84 (1.36, 2.79) |
| HDL-C (mmol/L) | 1.10 (0.92, 1.99) | 1.11 (0.91, 2.08) | 1.07 (0.93, 1.61) | 1.08 (0.97, 1.17) |
| LDL-C (mmol/L) | 2.57 (1.36, 3.19) | 2.54 (1.35, 3.24) | 2.63 (1.735, 3.095) | 2.95 (2.31, 3.09) |
| Insulin (mIU/L) | 19.11 (12.72, 26.69) | 19.02 (12.46, 25.49) | 19.60 (14.395, 28.44) | 16.22 (10.83, 27.40) |
| HbA1c (%) | 5.8 (5.4, 6.6) | 5.7 (5.4, 6.5) | 6.0 (5.5, 6.8) | 5.7 (5.3, 6.6) |
| Fasting glucose (mmol/L) | 5.58 (5.01, 7.01) | 5.49 (5.01, 6.48) | 5.85 (5.05, 7.68) | 5.49 (4.94, 7.06) |
| HOMA-IR | 5.15 (3.21, 7.42) | 4.87 (3.06, 6.88) | 5.50 (3.74, 8.37) | 5.33 (2.34, 6.98) |
| Ferritin (ng/mL) | 116.48 (48.56, 207.93) | 109.64 (45.92, 190.11) | 122.30 (52.06, 259.12) | 85.99 (28.64, 198.42) |
| Platelet (∗109/L) | 267.91 (228.47, 310.17) | 268.70 (230.02, 307.71) | 267.80 (227.01, 313.94) | 277.02 (240.51, 311.52) |
Data are presented as n (%) or median (interquartile range; non-normally distributed variables). See also Table S2. NL, normal liver; NAFL, non-alcoholic fatty liver; NASH, non-alcoholic steatohepatitis. BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; γ-GT, γ-glutamyl transferase; TG, total triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HOMA-IR, homeostatic model assessment for insulin resistance.